Last reviewed 2026-04-20 · How we verify

VLA15 (vla15)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Injection site pain
• Myalgia
• Headache
• Injection site erythema
• Fatigue
• Injection site swelling
• Injection site induration
• Arthralgia
• Nausea
• Influenza like illness
• Upper respiratory tract infection
• Pyrexia

Key clinical trials

• A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults (PHASE3)
• Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population (PHASE2)
• An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) (PHASE3)
• Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children (PHASE3)
• Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis (PHASE2)
• Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis (PHASE1)
• Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study. (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• VLA15 CI brief — competitive landscape report
• VLA15 updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI